The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy is a paralytic syndrome, causing considerable disability and even death. In controlled clinical trials, plasma exchange prevented or ameliorated neurological deficits, but the efficacy of immune globulin infusion remains unproved. Also unknown is whether immune globulin infusion is as effective, or more effective, than plasma exchange and what dosages and frequencies are best. In this observer‐blinded study, using some objective end points not subject to bias (e.g., summated compound muscle action potential), 20 patients with progressive or static polyneuropathy were randomly assigned to receive either of the two treatments for 6 weeks, followed by a washout period, and then were assigned to receive the other treatment. Plasma exchange (twice a week for 3 weeks then once a week for 3 weeks) and immune globulin infusion (0.4 gm/kg once a week for 3 weeks, then 0.2 gm/kg once a week for the next 3 weeks) were used. End points assessed before and after treatment schedules were neurological disability score; muscle weakness of the neurological disability score; summated compound muscle action potentials of ulnar, median, and peroneal nerves; summated sensory nerve action potentials of ulnar and sural nerves; and vibratory detection threshold of the great toe using CASE IV. Observers were masked as to treatment used. Of 20 patients, 13 received both treatments whereas 4 did not worsen sufficiently to receive the second treatment—1 patient left the study during and 2 after the first treatment to receive unscheduled treatment elsewhere. Of the 17 patients who received plasma exchange in either treatment period, statistically significant improvement occurred in the neurological disability score (38.3 ± 34.6 points, mean±standard deviation, p < 0.001), weakness subset of the score (33.4 ±29.5 points, p < 0.001), and summated compound muscle action potentials (3.7 ±3.5 mV, p < 0.001). This improvement is large and unequivocal, being equivalent to a change from a 50% bilateral weakness of pelvic and lower limb muscles to no weakness. Of the 15 patients who received immune globulin infusion in either schedule, the comparable changes were as follows: the nerological score, 36.1± 32.0 points (p = 0.006); the weakness subset of the neurological score, 31.4 ±31.5 points (p < 0.002); and summated muscle action potentials, 3.3 ±2.8 mV (p < 0.001). In a comparison of the change in neuropathic end points between the two treatments, statistically significant differences were not found for any end point. In an open trial of 8 patients, to determine the frequency and dosage of immune globulin infusion needed to maintain good function, we found that frequency could be titrated by assessing the neurological disability score and the summated muscle action potentials at 6‐week intervals. The dosage and frequency required to achieve a high functional level were quite variable among patients. Both treatments are efficacious in ameliorating neurological deficit in chronic inflammatory demyelinating polyradiculoneuropathy. The effect is large, but for most patients is short‐lived, requiring continued intermittent treatment for maximal or sustained improvement. For schedules of treatment that cost approximately the same, a clear difference in efficacy was not shown between plasma exchange and immune globulin infusion. Since immune globulin can be infused without expensive devices and can be given in the home, it may be the preferable treatment. The frequency and dosage of infused globulin needed to maintain improvement was quite variable (from as little as 0.025 gm/kg once every 10 days to 0.4 gm/kg [seldom more] every 2–4 days).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
Chronic Inflammatory Polyradiculoneuropathy
Millichap, J. G. (1997) · Pediatric Neurology Briefs · doi:10.15844/pedneurbriefs-11-12-6 · Cited by 822
Human diabetic endoneurial sorbitol, fructose, and myo‐inositol related to sural nerve morphometry
Dyck, P. J., Sherman, W. R., Hallcher, L. M., John Service, F., O'Brien, P. C., Grina, L. A., Palumbo, P. J., & Swanson, C. J. (1980) · Annals of Neurology · doi:10.1002/ana.410080608 · Cited by 511
Self-citationPlasma Exchange in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Dyck, P. J., Daube, J., O'Brien, P., Pineda, A., Low, P. A., Windebank, A. J., & Swanson, C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140801 · Cited by 489
Self-citationPrednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment
Dyck, P. J., O'Brien, P. C., Oviatt, K. F., Dinapoli, R. P., Daube, J. R., Bartleson, J. D., Mokri, B., Swift, T., Low, P. A., & Windebank, A. J. (1982) · Annals of Neurology · doi:10.1002/ana.410110205 · Cited by 483
Self-citationEfficiency of plasma exchange in Guillain‐Barré syndrome: Role of replacement fluids
French Cooperative Group on Plasma Exchange in Guillain‐Barrk Syndrome (1987) · Annals of Neurology · doi:10.1002/ana.410220612 · Cited by 457
Chelimsky, T., & Katirji, B. (1994) · Neurology · doi:10.1212/wnl.44.4.784-a · Cited by 433
Plasma Exchange in Polyneuropathy Associated with Monoclonal Gammopathy of Undetermined Significance
Dyck, P. J., Low, P. A., Windebank, A. J., Jaradeh, S. S., Gosselin, S., Bourque, P., Smith, B. E., Kratz, K. M., Karnes, J. L., Evans, B. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252105 · Cited by 301
Self-citationMcKhann, G. M., Griffin, J. W., Cornblath, D. R., Mellits, E. D., Fisher, R. S., Quaskey, S. A., & The Guillain‐Barré Syndrome Study Group (1988) · Annals of Neurology · doi:10.1002/ana.410230406 · Cited by 275
Doorn, P. A. V., Brand, A., Strengers, P. F. W., Meulstee, J., & Vermeulen, M. (1990) · Neurology · doi:10.1212/wnl.40.2.209 · Cited by 274
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Schwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly‐Smith, L., Delaney, M., Dunbar, N. M., Witt, V., Wu, Y., & Shaz, B. H. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21470 · Cited by 793
Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Self-citationConnelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Update on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
ORANGE, J., HOSSNY, E., WEILER, C., BALLOW, M., BERGER, M., BONILLA, F., BUCKLEY, R., CHINEN, J., ELGAMAL, Y., & MAZER, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.015 · Cited by 653
Hughes, R., Bensa, S., Willison, H., Van Den Bergh, P., Comi, G., Illa, I., Nobile‐Orazio, E., Van Doorn, P., Dalakas, M., Bojar, M., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1088 · Cited by 628
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
Szczepiorkowski, Z. M., Bandarenko, N., Kim, H. C., Linenberger, M. L., Marques, M. B., Sarode, R., Schwartz, J., Shaz, B. H., Weinstein, R., Wirk, A., et al. (2007) · Journal of Clinical Apheresis · doi:10.1002/jca.20129 · Cited by 546
Joint Task Force of the EFNS and the PNS (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00245.x · Cited by 539
Van den Bergh, P. Y. K., van Doorn, P. A., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Allen, J. A., Attarian, S., Blomkwist‐Markens, P. H., Cornblath, D. R., Eftimov, F., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14959 · Cited by 530
Van den Bergh, P. Y. K., van Doorn, P. A., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Allen, J. A., Attarian, S., Blomkwist‐Markens, P. H., Cornblath, D. R., Eftimov, F., et al. (2021) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12455 · Cited by 520
Chronic Inflammatory Demyelinating Polyneuropathy
Köller, H., Kieseier, B. C., Jander, S., & Hartung, H.-P. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041347 · Cited by 511
Szczepiorkowski, Z. M., Winters, J. L., Bandarenko, N., Kim, H. C., Linenberger, M. L., Marques, M. B., Sarode, R., Schwartz, J., Weinstein, R., & Shaz, B. H. (2010) · Journal of Clinical Apheresis · doi:10.1002/jca.20240 · Cited by 508
Total neuropathy score: Validation and reliability study
Cornblath, D. R., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., & Joh, T. (1999) · Neurology · doi:10.1212/wnl.53.8.1660 · Cited by 449
Hahn, A. F., Bolton, C. F., Zochodne, D., & Feasby, T. E. (1996) · Brain · doi:10.1093/brain/119.4.1067 · Cited by 439
Clinical spectrum of chronic acquired demyelinating polyneuropathies
Saperstein, D. S., Katz, J. S., Amato, A. A., & Barohn, R. J. (2001) · Muscle & Nerve · doi:10.1002/1097-4598(200103)24:3<311::aid-mus1001>3.0.co;2-a · Cited by 417
Dyck, P. J., Davies, J. L., Litchy, W. J., & O'Brien, P. C. (1997) · Neurology · doi:10.1212/wnl.49.1.229 · Cited by 382
Self-citationGorson, K. C., Allam, G., & Ropper, A. H. (1997) · Neurology · doi:10.1212/wnl.48.2.321 · Cited by 329
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
Dalakas, M. C. (2004) · JAMA · doi:10.1001/jama.291.19.2367 · Cited by 329
Intravenous immunoglobulin in neurology—mode of action and clinical efficacy
Lünemann, J. D., Nimmerjahn, F., & Dalakas, M. C. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.253 · Cited by 301
Advances in the diagnosis, pathogenesis and treatment of CIDP
Dalakas, M. C. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.121 · Cited by 296
van der Mech�, F. G. A., & van Doorn, P. A. (1995) · Annals of Neurology · doi:10.1002/ana.410370704 · Cited by 131
Plasmapheresis in immunologically mediated polyneuropathies.
Kiprov, D. D., & Hofmann, J. C. (2003) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.2003.00028.x · Cited by 13
Metadata
- Authors
- Dyck, P. J., Litchy, W. J., Kratz, K. M., Suarez, G. A., Low, P. A., Pineda, A. A., Windebank, A. J., Karnes, J. L., & O'Brien, P. C.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1994-12
- Volume
- 36
- Issue
- 6
- Pages
- 838-845
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2093997579
- Cited by
- 471
- References
- 17
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.